These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 11927077

  • 1. [Guidelines for respiratory syncytial virus prophylaxis. An update].
    Carbonell-Estrany X, Quero Jiménez J.
    An Esp Pediatr; 2002 Apr; 56(4):334-6. PubMed ID: 11927077
    [Abstract] [Full Text] [Related]

  • 2. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X.
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [Abstract] [Full Text] [Related]

  • 3. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, IRIS Study Group.
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [Abstract] [Full Text] [Related]

  • 4. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia.
    Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F, Gouyon JB, Burgundy Perinatal Network.
    Pediatr Pulmonol; 2007 Mar; 42(3):189-92. PubMed ID: 17243184
    [Abstract] [Full Text] [Related]

  • 5. [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic].
    Grupo de Hospitales Benazuza.
    An Esp Pediatr; 2002 Apr; 56(4):293-7. PubMed ID: 11927095
    [Abstract] [Full Text] [Related]

  • 6. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.
    Grimaldi M, Gouyon B, Michaut F, Huet F, Gouyon JB, Burgundy Perinatal Network.
    Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942
    [Abstract] [Full Text] [Related]

  • 7. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM.
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [Abstract] [Full Text] [Related]

  • 8. Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease?
    Elhassan NO, Stevens TP, Sorbero ME, Dick AW, Guillet R, Hall CB.
    Pediatr Infect Dis J; 2003 Nov; 22(11):939-43. PubMed ID: 14614363
    [Abstract] [Full Text] [Related]

  • 9. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O.
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [Abstract] [Full Text] [Related]

  • 10. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR.
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [Abstract] [Full Text] [Related]

  • 11. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
    Fitzgerald DA.
    Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
    [Abstract] [Full Text] [Related]

  • 12. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit.
    Cox RA, Rao P, Brandon-Cox C.
    J Hosp Infect; 2001 Jul; 48(3):186-92. PubMed ID: 11439005
    [Abstract] [Full Text] [Related]

  • 13. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [Abstract] [Full Text] [Related]

  • 14. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T, Rozé JC, Fauroux B, French Pediatricians' Group of Sunagis Patients' Name-Based Programs.
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [Abstract] [Full Text] [Related]

  • 15. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden.
    Navér L, Eriksson M, Ewald U, Linde A, Lindroth M, Schollin J.
    Acta Paediatr; 2004 Nov; 93(11):1470-3. PubMed ID: 15513574
    [Abstract] [Full Text] [Related]

  • 16. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M, Nerwen C, Boron M, Cohen A, VanVeldhuisen P, Harrington M, Groothuis J, Palivizumab Outcomes Registry Group.
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [Abstract] [Full Text] [Related]

  • 17. Respiratory syncytial virus risk factors in late preterm infants.
    Lanari M, Silvestri M, Rossi GA.
    J Matern Fetal Neonatal Med; 2009 Oct; 22 Suppl 3():102-7. PubMed ID: 19925369
    [Abstract] [Full Text] [Related]

  • 18. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age.
    Park HW, Lee BS, Kim AR, Yoon HS, Kim BI, Song ES, Kim WT, Lim J, Kim S, Jin HS, Byun S, Chee DH, Kim KS.
    Pediatr Infect Dis J; 2012 Aug; 31(8):e99-104. PubMed ID: 22531234
    [Abstract] [Full Text] [Related]

  • 19. [Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation)].
    Figueras Aloy J, Carbonell Estrany X, Comité de Estándares de la Sociedad Española de Neonatología.
    An Pediatr (Barc); 2010 Aug; 73(2):98.e1-4. PubMed ID: 20621574
    [Abstract] [Full Text] [Related]

  • 20. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B, Steele S, Janes M, Pinelli J.
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.